Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

No, You Do Not Hear the Fat Lady Warming Up

Those who never predicted a financial collapse in the first place are now edging closer to the swamp to dip their toes into the water. Now they are suggesting, perhaps we could have a recession. " Forget that. You cannot have every supply chain in the world chopped in ...
Streetwise Reports | March 30, 2020 |

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

The new data are reviewed and updates are provided on Can-Fite BioPharma's other clinical studies, including one for COVID-19, in this Dawson James research report. In an April 20 research note, Dawson James analyst Jason Kolbert wrote that results from Can...
Streetwise Reports | April 23, 2020 |

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. In a Sept. 26 research note, ROTH Capital Partners analyst Jerry Isaacson reported that AzurRx BioPharma Inc.'s (AZRX:NASDAQ) Phase 2 OPTION trial for lead candidate MS1819 in cystic ...
Streetwise Reports | October 1, 2019 |

NetApp (NTAP) suffering from low earnings expectations

The computer hardware sector has been an outperformer during the past year, with the NYSE Arca Computer Hardware Index ( HWI ) soaring more than 87% during the prior 52 weeks. Comparatively, the tech-laden, and market-leading, Nasdaq Composite (COMP) has rallied some 48% dur...
Joseph Hargett | October 28, 2012 |

Will Straightup Resources Inc. become the next Great Bear Resources?

Straightup Resources Inc. (CSE: ST) is a new public company focused on advancing its flagship RLX and Belanger properties located in the Red Lake District of Ontario, Canada. Red Lake is one of the more prolific gold mining districts in the world with ~29 million oz gold hav...
James O'Rourke | June 30, 2020 |

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease

The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. In a Feb. 19 research note, analyst Yasmeen Rahimi reported that CymaBay Therapeutics Inc. (CBAY:NASDAQ) is having a strong Q1/19 with respect to cont...
Streetwise Reports | February 26, 2019 |

Gold and Silver: Capitulation Time

"People everywhere are being fed propaganda, lies and false stimuli of all kinds, but deep in their hearts, deep in their instincts, they know something is wrong."—G. Edward Griffin, author of The Creature from Jekyll Island My usual weekend missive was mildly delay...
Streetwise Reports | November 13, 2019 |

From COVID to Nicotine Treatments, this Bio Stock is One to Watch

(Image via Lexaria Bioscience Corp.) There’s no shortage of excitement over potential COVID-19 vaccines. Just looking at the response to news around these developments is evidence of that, and one Company is working on a transformative, patented tech...
Stockhouse Editorial | December 1, 2020 |

Gold lining for this moly junior

DENIO, Nevada -- I just toured the historic Ashdown Molybdenum/Gold Mine . Ashdown produced 16,000 ounces of gold (averaging 10 g/t) between 1880 and 1942 and was actively explored by some of the world’s largest mining companies in the 1980s and 90s. The ...
Andy Hoffman | October 28, 2012 |

3 Tips for Picking Junior Gold Stocks

As the correction in gold stocks continues and as it’s likely to endure for the time being, we take a step back and share some tips for selecting individual junior gold companies. The current correction may provide the last chance to buy before the bull mar...
Jordan Roy-Byrne, CMT | October 9, 2019 |
1 2 3 4